This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $115,414 to the Beckman Research Institute of the City of Hope to conduct research aimed at concurrently eradicating pathogenic plasma cells and their precursors in systemic lupus erythematosus (SLE). The award, which runs from September 2024 to August 2026, will support two specific aims: 1) determining the effect of knockdown of the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $149,008 Cooperative Agreement under the Trans-NIH Research Support program (CFDA 93.310) to Cartesian Therapeutics Inc. to develop and evaluate a novel cell therapy for the treatment of systemic lupus erythematosus (SLE). The funding will support a Phase 2A clinical trial and the design of a subsequent randomized, placebo-controlled Phase 2B trial to test "Descartes-08", an RNA-engineered chimeric antigen...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $260,445 to Brigham & Women's Hospital Inc. to conduct research on identifying biomarkers associated with nasal polyp recurrence in patients with aspirin-exacerbated respiratory disease (AERD). The key objectives are to: 1) Establish a biomarker-based predictive model for nasal polyp recurrence in AERD patients,...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $196,245 to the Regents of the University of Michigan to develop predictive biomarkers for treatment failure in patients with connective tissue disease-associated interstitial lung disease (CTD-ILD). The primary objectives are to: 1) determine forced vital capacity (FVC) trajectories and cumulative incidence of treatment failure across CTD-ILD subtypes; 2)...
The federal Project Grant award R21AI183127, totaling $423,500.00, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The primary goal of this 2-year award to Loyola University of Chicago is to develop novel antibodies that specifically target autoreactive B cells as a potential therapeutic approach for treating systemic lupus erythematosus (SLE), particularly in African American patients...
This Project Grant award of $539,218.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research to develop and validate a prediction model for progression-free survival in patients with myositis-associated interstitial lung disease (ILD). The research aims to identify novel biomarkers and subphenotypes to better understand the clinical and biological heterogeneity of myositis-ILD. The award was granted to The Trustees of the...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) totaling $1,475,821 will fund a study to address key challenges in the diagnosis and treatment of immune checkpoint inhibitor-associated acute interstitial nephritis (ICI-AIN). The researchers plan to: Evaluate the accuracy of the biomarker CXCL9 in urine for diagnosing ICI-AIN and distinguishing it from other causes of...
This Project Grant award of $413,860, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to investigate the interactions between non-tuberculous mycobacteria (NTM) infections, specifically Mycobacterium abscessus (MAB), and the onset/progression of systemic lupus erythematosus (SLE). The research will utilize preclinical mouse models and ex vivo models with fetal...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $3,717,718 Cooperative Agreement under the Cardiovascular Diseases Research program (CFDA 93.837) to Duke University to conduct the "LOW DOSE COLCHICINE IN PATIENTS WITH PERIPHERAL ARTERY DISEASE TO ASSESS RESIDUAL VASCULAR RISK (LEADER-PAD)" clinical trial. This 4-year study, starting on September 25, 2024, aims to enroll 1,000 U.S. participants as part of a larger 6,150-patient international trial. The trial will...
The University of California, San Francisco will conduct research on NR4A family proteins as markers and mediators of B cell tolerance in systemic lupus erythematosus (SLE) under a three-year, $738,631 Project Grant from the Department of the Army Medical Command. The grant is part of the Military Medical Research and Development program administered by the Department of Defense and aims to transform military and public health through innovative medical research solutions for battlefield...